
Capricorn Metals (ASX: CMM) delivers strong cash generation and mine expansion momentum, positioning for 300koz annual production through Karlawinda and Mt Gibson growth. Premium valuation reflects execution strength and long-life margins.

Lotus Resources (ASX: LOT) jumped 14% to $0.66 as investors responded to improving uranium market sentiment and progress at its Kayelekera and Letlhakane projects. The company continues to ramp up production in Malawi while advancing plans to become a potential 5.5 M lb-per-year uranium producer.

Auckland Airport (ASX: AIA) delivers steady earnings growth, strong passenger recovery, and disciplined infrastructure execution, positioning New Zealand’s gateway for long‑term value creation.

Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.

Inoviq shares plunged after sample-quality issues delayed validation of its EXO-OC ovarian cancer test, despite improved algorithm performance. The sharp reversal has shifted investor focus from growth potential to execution risks, timelines, and confidence in the company’s development strategy.

Manuka Resources is retracing after its May rally as investors await production milestones. With gold processing expected in July and silver production targeted for September, the market is looking for operational results to confirm the company's restart strategy.
...